BeiGene Financial Activities - Other 2014-2024 | ONC
BeiGene annual/quarterly financial activities - other history and growth rate from 2014 to 2024. Financial activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the financing activities section of the Cash Flows Statement.
- BeiGene financial activities - other for the quarter ending September 30, 2024 was $0.003B, a INF% increase year-over-year.
- BeiGene financial activities - other for the twelve months ending September 30, 2024 was $6M, a INF% increase year-over-year.
- BeiGene annual financial activities - other for 2023 was $0B, a NAN% decline from 2022.
- BeiGene annual financial activities - other for 2022 was $0B, a NAN% decline from 2021.
- BeiGene annual financial activities - other for 2021 was $0B, a 100% decline from 2020.
BeiGene Annual Financial Activities - Other
(Millions of US $) |
| 2023 |
$ |
| 2022 |
$ |
| 2021 |
$ |
| 2020 |
$617 |
| 2019 |
$4 |
| 2018 |
$-6 |
| 2017 |
$14 |
| 2016 |
$-2 |
| 2015 |
$-0 |
| 2014 |
$0 |
| 2013 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
